Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mobile phones

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

UK flag

Education at heart of new UK diabetes guidelines

NICE recommends new standards for adults with type 1 and children with either type 1 or type 2

- PMLiVE

The challenge of poor adherence in type 2 diabetes

How can pharma help address this growing problem?

- PMLiVE

The behavioural science of adherence

A broad range of factors can influence a person’s decision not to take treatment as prescribed but these can now be seen to be underpinned by academic principles

- PMLiVE

Sharing good diabetes practice in the NHS

Breaking down healthcare silos to demonstrate the benefits and adaptability of diabetes care initiatives

- PMLiVE

Diabetes puts economic growth at risk, says IDF

Comments come on World Diabetes Day

- PMLiVE

The rising prevalence of diabetes in Europe

The condition is still an unstoppable epidemic

- PMLiVE

Servier licenses device that could ‘reshape’ diabetes care

Tiny pump implant to deliver GLP-1 agonist

Novo taps behavioural change for diabetes programme’s re-launch

Adds health coach function to Cornerstones4Care

Eli Lilly HQ

Lilly launches GLP-1 agonist Trulicity in US

Once-weekly treatment will challenge GSK's Tanzeum, AZ's Bydureon and Novo's Victoza in diabetes

- PMLiVE

MSD launches diabetes programme with pharmacy network

Will support medicines optimisation in people prescribed Januvia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links